Cataract

Higher-concentration drug statistically superior to vehicle for achieving resolution of inflammation

Phase IIb, III data show anti-inflammatory/mydriatic agent reduces miosis

Study shows better reproducibility with devices dedicated to standardizing capsulorhexis

The FDA has approved Bausch + Lomb’s Trulign lens, a toric posterior chamber IOL that corrects for astigmatism and has the capacity to deliver improved vision across a natural range of focus.

Survey results paint portrait of trends, technology’s effect on cataract practice

Lens demonstrated excellent rotational stability, visual outcomes in clinical trials

Once-daily dosing delivers rapid, potent control of postoperative pain, inflammation

Wound construction, IOL calculations, lens selection among variables in special population

Lens assessment with femtosecond laser imaging offers opportunity for cataract outcomes

Two cases illustrate benefits in managing dry eye before, after surgery with premium lens implantation

Challenging cases achieve good refractive outcomes with intraoperative aberrometry

Although cataract surgery is already the most-used intervention for glaucoma, a growing number of glaucoma specialists want to see timely glaucoma surgery accepted and reimbursed as an appropriate intervention for the long-term management of glaucoma, said Kuldev Singh, MD, MPH, professor and chief of the Glaucoma Service at Stanford University, Stanford, CA.

New data suggest that it may be time to stop worrying about broad inclusion criteria when evaluating patients with cataracts for potential femtosecond laser surgery. A retrospective review of more than 800 consecutive cases found that the technology provides high precision in the treatment of challenging cases with broad inclusion criteria, said H. Burkhard Dick, MD.

Physicians who wonder if they should make the investment in a new model of surgical system they currently use and like, the answer could be yes. Data presented by Barry Schechter, MD, showed a 22% time savings in uncomplicated cataract procedures with new equipment.

Whether a surgeon uses a laser for cataract surgery or manual methods may not make much of a difference in terms of postoperative inflammation. That at least is the experience of H. Burkhard Dick, MD, professor and chairman of ophthalmology and director of the University Eye Clinic Bochum, Bochum, Germany.

New clinical data suggest that an improved intraoperative aberrometer can help improve clinical outcomes for patients who receive an aspheric, hydrophobic IOL, said Dee Stephenson, MD, of Stephenson Eye Associates in Venice, FL.

Ophthalmology has a history of “strange,” and actually that may be good for the specialty. Of all the specialties of medicine, ophthalmology keeps seeing innovation evolve on a regular basis. The technology in this market is always evolving and it keeps getting better and more efficient.

Upgrade may make traditional manual lens delivery a thing of the past

Third annual meeting delivers on innovative educational program

Large series shows increased safety, efficiency, efficacy with laser-assisted cataract surgery

Ability to maneuver without entering the eye a plus in some difficult cataract surgeries

Novel procedures bring glaucoma surgery into realm of cataract, corneal subspecialists

Laser refractive cataract surgery delivers improved results with easy learning curve

Surgeon outlines technique pearls for success in laser refractive lens surgery

Cases illustrate utility of laser system when unstable lenses are present

Use of arcuate incisions in femtosecond laser cataract surgery are highlighted in this brief video presentation from Eric D. Donnenfeld, MD.

OptiMedica Corp. has received a patent for the Catalys Precision Laser System relating to the fundamental technology underlying laser cataract surgery.

Bausch + Lomb and CROMA have donated 50,000 units of bromfenac sodium sesquihydrate (Yellox) to projects in Africa sponsored by Light for the World.

Alcon has announced the launch of nepafenac ophthalmic suspension 0.3% (Ilevro), a new once-daily treatment option for pain and inflammation associated with cataract surgery.